Date Time
A Year Like No Other: Most-Read CU Anschutz Stories of 2020
Here’s a look back at the most popular stories in the CU Anschutz Newsroom in this pivotal year
It’s safe to say that 2020, rife with the disruptions, challenges and uncertainties that a global pandemic brings, has been a pivotal year. With SARS-CoV-2 vaccines rolling out, and the promise of a healthier and brighter 2021, science has vaulted in preeminence worldwide.
The University of Colorado Anschutz Medical Campus was at the center of research and patient care, including as a site for the Moderna vaccine clinical trials. It was a year bursting with news about how the entire CU Anschutz community rallied to make a difference in the crisis.
Ordinary water may be an unexpected tool against obesity hormone
Vasopressin, a hormone linked to diabetes and obesity, may be suppressed by water, potentially making it a tool against metabolic syndrome. The findings come from the University of Colorado Anschutz Medical Campus where researchers found that fructose stimulates the hormone and water suppresses it at least in lab rodents.
The study, which was recently published in
JCI Insight, involved feeding mice water mixed with fructose. This beverage was found to trigger the production of vasopressin in the brain, which is elevated in people who have diabetes or obesity. The hormone works to maintain water levels in the body.
National Lipid Association Releases Official Scientific Statement on Coronary Artery Calcium Scoring for ASCVD Risk Reduction
JACKSONVILLE, Fla., Dec. 12, 2020 (GLOBE NEWSWIRE) The National Lipid Association (NLA) today announced the release of its official scientific statement on coronary artery calcium (CAC) scoring for atherosclerotic cardiovascular disease (ASCVD) risk reduction. The statement provides updates on the evidence-based appropriate use of CAC scoring and makes practical recommendations to aid clinicians in primary prevention treatment decision-making in contemporary clinical practice.
“Coronary calcium scoring is the best available non-invasive marker of cardiovascular risk,” Stated the corresponding author, Carl E. Orringer, MD, Associate Professor Medicine at the University of Miami, Miller School of Medicine, Cardiovascular Division. “This manuscript addresses the key questions that clinicians have about this test and provides up-to-date, evidence-based r
Share:
JACKSONVILLE, Fla., Dec. 12, 2020 (GLOBE NEWSWIRE) The National Lipid Association (NLA) today announced the release of its official scientific statement on coronary artery calcium (CAC) scoring for atherosclerotic cardiovascular disease (ASCVD) risk reduction. The statement provides updates on the evidence-based appropriate use of CAC scoring and makes practical recommendations to aid clinicians in primary prevention treatment decision-making in contemporary clinical practice. Coronary calcium scoring is the best available non-invasive marker of cardiovascular risk, Stated the corresponding author, Carl E. Orringer, MD, Associate Professor Medicine at the University of Miami, Miller School of Medicine, Cardiovascular Division. This manuscript addresses the key questions that clinicians have about this test and provides up-to-date, evidence-based recommendations for optimal use of this technology for cardiovascular disease prevention.
New collaborative study to address key questions about COVID-19
A new nationwide study of more than 50,000 individuals is underway to determine factors that predict disease severity and long-term health impacts of COVID-19.
Researchers at the University of Colorado Anschutz Medical Campus are part of the NIH-funded study, the Collaborative Cohort of Cohorts for COVID-19 Research (C4R) Study, which includes 37 academic medical centers across the country. Participants in C4R are currently enrolled in 14 long-term studies at cohort institutions.
The new collaborative study will be able to answer important questions about COVID-19 that cannot be answered by smaller, individual studies that have been set up to study COVID-19.